AIM
OCUL icon

Acrospire Investment Management’s Ocular Therapeutix OCUL Stock Holding History

Acrospire Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,056
Closed -$51K – 2413
2016
Q4 		$51K Buy
+6,056
New +$47K 0.02% 1389

Other funds holding OCUL

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Acrospire Investment Management's OCUL Position: Q1 2017 in Review

Acrospire Investment Management sold out of Ocular Therapeutix (OCUL) in Q1 2017, closing a stake of 6,056 shares — an estimated $51K sold.

Acrospire Investment Management first reported a position in OCUL in Q4 2016 and held it in 1 quarter. The position peaked at $51K in Q4 2016. 73 funds tracked by Wall St. Rank hold OCUL as of Q1 2017.

  • Acrospire Investment Management reported no remaining Ocular Therapeutix position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 6,056 Ocular Therapeutix shares in Q1 2017, an estimated $51K.
  • Acrospire Investment Management first reported a position in Ocular Therapeutix in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Ocular Therapeutix position peaked at $51K in Q4 2016.
  • 73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.